Public court records · Regulatory sources · Independently maintained Data as of: 2026-10-21 · Not legal advice

Suboxone (Buprenorphine) Dental Injury Lawsuit

US MDL Consolidated Last verified 2026-10-03

MDL 3092 · N.D. Ohio

Lawsuits allege that Suboxone (buprenorphine/naloxone), a treatment for opioid use disorder, causes serious dental problems — including tooth decay, jaw pain and tooth loss..

Overview

Lawsuits allege that Suboxone (buprenorphine/naloxone), a treatment for opioid use disorder, causes serious dental problems — including tooth decay, jaw pain and tooth loss. The FDA reported 305 dental adverse-event reports for buprenorphine products (131 serious) and required a label update in 2022 (per FDA). The federal product-liability claims are consolidated in MDL 3092 in the Northern District of Ohio before Judge J. Philip Calabrese — 2,022 pending per the JPML report of October 1, 2026 (2,112 historically), with firm-page trackers listing roughly 2,200 including new filings (per LexGenius tracker, 2026) — and a separate antitrust case exists (per dockets). A 2022 JAMA study found higher rates of dental adverse events among sublingual buprenorphine/naloxone users (per the study, as cited by firm pages). No global settlement has been announced (per firm pages, 2026).

Key people

Companies involved

Settlement amounts

No global settlement for the dental claims as of the Oct 21 2026 check (per firm pages). Claims are consolidated in MDL 3092, N.D. Ohio — 2,022 actions pending per the JPML report of Oct 1, 2026 (per JPML); amounts are case-specific. No outcome can be promised.

Figures above are as reported by the cited sources — not a promise of any individual outcome.

Last updated: 2026-10-21

Full breakdown: settlement amounts page →

Case count

2,022 cases as of October 1, 2026
MonthFiled casesΔ
Oct 1, 20262,022+173
Mar 2, 20261,849—

Key dates

  1. October 1, 2026JPML report: 2,022 actions pending in MDL 3092 (2,112 historically); firm-page trackers list roughly 2,200 including new filings (per JPML report, Oct 1 2026; LexGenius tracker)
  2. March 2, 2026JPML report: 1,849 pending cases in MDL 3092 (per JPML report of Mar 2, 2026, cited by LexGenius tracker)
  3. January 25, 2024JPML hears arguments on consolidating federal Suboxone lawsuits into MDL 3092, N.D. Ohio (per A. M. Law timeline and JPML)
  4. June 1, 2022FDA mandates label update adding dental risks to buprenorphine products (per FDA, 2022)
  5. January 15, 2022FDA safety communication on buprenorphine dental risks — 305 adverse-event reports, 131 serious (per FDA, 2022)

Updates

  • Updated Oct 3, 2026Update (Oct 2026, US): Suboxone dental — MDL 3092, N.D. Ohio (Judge Calabrese): 1,849 pending per JPML (Mar 2, 2026); ~2,200 tracked incl. new filings (per LexGenius, 2026); no settlement (per firm pages).
  • Updated Sep 1, 2026Correction: dental injury cases are consolidated in MDL 3092 (N.D. Ohio, Judge Calabrese, per JPML), not pending as individual cases only.
  • Updated Aug 1, 2026Seeded from research (Aug 2026): active intake by multiple plaintiff firms; FDA 305 dental adverse-event reports, 131 serious (per FDA, 2022).

Last updated: 18 days ago

Full changelog →

Notable filings

No notable filings recorded yet. Docket entries are added from public court records as they appear.

FAQ

Frequently asked questions about this case record, answered from the public record.

What is the Suboxone dental lawsuit about?

Claimants allege that Suboxone (buprenorphine/naloxone), a treatment for opioid use disorder, causes serious dental problems — including tooth decay, jaw pain, and tooth loss (per complaints). The federal cases are consolidated in MDL 3092, N.D. Ohio, before Judge J. Philip Calabrese (per JPML).

What did the FDA find?

The FDA reported 305 dental adverse-event reports for buprenorphine products (131 serious) and required a label update in 2022 (per FDA).

Is there an MDL?

Yes — the dental injury cases are consolidated in MDL 3092, In re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, N.D. Ohio, before Judge J. Philip Calabrese (per JPML). A separate antitrust case also exists (per dockets).

Who is the defendant?

Reckitt, the manufacturer of Suboxone (per complaints and public records).

How much will victims receive?

No global settlement for the dental claims is on the public record as of August 2026 (per firm pages). Individual cases proceed in various federal courts; amounts are case-specific. No outcome can be promised.

How do I start a case review?

Use the free case review on this page. If you request it, your details are shared only with law firms working this matter. We are not a law firm and we do not promise any outcome.

Think this matters to you?

This page is neutral reference material — not legal advice. If you were affected, the next step is a free case review with a licensed attorney working this matter.

Start free case review →

By continuing you agree to our privacy policy. Your contact details are shared only with law firms working this matter, on request.